Clinical Trials
0
0 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
N/A
No trial phase data available
No trial data available
No trial data available
No approval data available
- Two U.S. biotech companies, Akston Biosciences and OKAVA Pharmaceuticals, have launched early-stage clinical trials testing GLP-1 weight-loss therapies for overweight and obese cats. - Approximately 61% of cats and 59% of dogs evaluated by U.S. veterinary professionals in 2022 were classified as overweight or obese, according to the Association for Pet Obesity Prevention. - Morgan Stanley analyst Simeon Gutman describes the trend as "an expansion from premiumization into medicalization," with U.S. pet spending projected to grow from $196 billion in 2025 to over $240 billion by 2030. - Top-line results from both feline GLP-1 clinical trials are expected later this year, though affordability concerns may constrain widespread adoption in veterinary medicine.
- Researchers at Hiroshima University discovered that fermented stevia extract demonstrates significantly greater cytotoxicity against pancreatic cancer cells compared to non-fermented stevia extract. - The fermentation process with Lactobacillus plantarum SN13T creates chlorogenic acid methyl ester (CAME), which selectively kills cancer cells while sparing healthy kidney cells. - Laboratory tests showed fermented stevia extract blocks cancer cells at specific life cycle phases and triggers apoptosis, offering potential for targeted cancer therapy development. - The findings represent early-stage research requiring animal and human studies before clinical applications can be considered.
- The Federal Trade Commission has approved AbbVie's $63 billion acquisition of Allergan after requiring the divestiture of key assets to preserve competition in specific therapeutic markets. - AbbVie and Allergan must divest Allergan's EPI treatment drugs Zenpep and Viokace to Nestlé, as the companies currently control 95% of the exocrine pancreatic insufficiency drug market. - The companies are also required to transfer brazikumab, an investigational IL-23 inhibitor for Crohn's disease and ulcerative colitis, to AstraZeneca to maintain future competition in inflammatory bowel disease treatments. - The FTC's ten-month investigation involved reviewing over 430,000 documents and conducting more than 40 interviews to assess potential competitive harm to consumers.
